Background
==========

Intravascular lymphoma, also known as intravascular lymphomatosis or angiotropic lymphoma and formerly known as malignant angioendotheliomatosis is a rare neoplastic disorder in which tumour cells are initially confined to the vascular lumen without parenchymal infiltration. While cases of systemic intravascular lymphoma are more frequently encountered, cases of intravascular lymphoma with restricted central nervous system (CNS) involvement (cIVL) are uncommon and only few patients that had been successfully treated have been reported so far \[[@B1]-[@B4]\]. We here present a case with a histologically confirmed cIVL that could be successfully treated with a high-dose methotrexate (HD-MTX) and rituximab-based chemotherapy regimen.

Case presentation
=================

A 69-year-old male Caucasian patient presented with recurrent transient amnestic aphasia and gait ataxia. Physical examination at the time of referral did not reveal any further pathological findings. B symptoms were absent. Serum LDH levels were twice the upper limit of normal, all other serum chemistry and differential blood count was negative. Cerebrospinal fluid (CSF) analysis revealed a normal cell count, protein levels were within the reference range, no atypical cells were detected. Initial magnetic resonance imaging (MRI) revealed a contrast-enhancing lesion in the pons (Figure [1A](#F1){ref-type="fig"}) and additional involvement of the left temporomesial area. A stereotactic biopsy was performed and histology revealed a CD20-antigen-expressing intravascular lymphoma with high proliferative activity (Figure [2A, B](#F2){ref-type="fig"}). Immunohistological evaluation of B-cell differentiation markers showed a BCL-6+ and MUM-1+−status. Subsequent staging (i.e. examination of the chest, abdomen and pelvis by contrast-enhanced computed tomography (CT) scan, bone marrow biopsy, slit lamp examination of the eye, spinal tap) did not reveal any systemic or additional CNS involvement.

![**MR imaging prior to and after HD-MTX-based chemotherapy (left column FLAIR, right column: contrast enhanced T1-weighted imaging)MR imaging prior to therapy (A) and at follow-up imaging at the end of 6 courses of chemotherapy with a strong reduction of contrast-enhancing lesions (B).** Nineteen months after initiation of treatment MR imaging showed complete regression of marked FLAIR hyperintensities and contrast enhancement in the brain stem **(C).**](2162-3619-1-37-1){#F1}

![**Histological examination of the tissue obtained by stereotactic biopsy of the brain stem.** Histology revealed CD20-immunopositive intravascular lymphoma cells **(A)** with a very high proliferative activity in MIB-1 immunohistochemistry **(B).**](2162-3619-1-37-2){#F2}

Chemotherapy according to the Bonn protocol was initiated in combination with rituximab therapy. The Bonn protocol comprises six 3-week courses with different combinations of HD-MTX (3 gm/m^2^ over 24 hours), ifosfamide, procarbazin, cytarabine, vinca alkaloids, and dexamethasone (for details see \[[@B5]\]). Rituximab was given at each course one day prior to the start of the HD-MTX infusion. During the 5th course, a transient and moderate increase in serum creatinine occurred, without a need for dose reduction in subsequent treatment courses. Vincristine was removed from the treatment protocol after development of mild signs of polyneuropathy. After the second course, the contrast-enhancing lesion showed already a partial remission; after the sixth course, only one small contrast-enhancing lesion remained that had to be qualified as unconfirmed complete remission since it further diminished in subsequent control MRIs without additional therapy (Figure [1A-C](#F1){ref-type="fig"}). The patient is now in complete clinical and radiographic remission 29 months after initial diagnosis of cIVL.

In this case report we demonstrate the successful therapy of a patient with cIVL, i.e. intravascular lymphoma limited to the CNS. The few reports available on the treatment of this medical condition are summarized in Table [1](#T1){ref-type="table"}. All cIVL cases in which progression and death due to systemic failure was explicitly mentioned were not included here. In some cases, lymphoma-directed specific therapy was not applied or the treatment modality was not reported. In these cases, survival did not exceed 4 months \[[@B6]-[@B9]\]. Conventional chemotherapy with anthracyline-based protocols (i.e. CHOP in 3 patients), radiotherapy, or corticosteroid therapy was not successful \[[@B10]-[@B12]\]. Using anthracycline-based chemotherapy which is effective in systemic intravascular lymphoma does not penetrate the intact blood--brain barrier (BBB), overall survival rarely exceeded 6 months. Our case, on the other hand, is in line with reports demonstrating that BBB-penetrating HD-MTX-based regimens may have considerable efficacy. Seven patients treated with HD-MTX alone or in combination with CHOP survived 6--20 months \[[@B1],[@B13],[@B14]\]. In a separate study, three patients with cIVL receiving HD-MTX-based chemotherapy showed progression-free survival times of 2, 20 and 48 month \[[@B1]-[@B3]\]. One additional case report presented a patient receiving HD-MTX + R-CHOP followed by consolidation therapy with high-dose chemotherapy (thiotepa, busulfan, and cyclophosphamide) and autologous stem-cell rescue. This patient survived for at least 19 months after treatment \[[@B4]\]. It remains unclear why HD-MTX-based, i.e. blood--brain barrier (BBB)-penetrating therapy is needed for successful therapy of cIVL and which are the optimal combination partners for MD-MTX therapy. Also, it is unclear why regimens that do not penetrate the BBB but are effective in other forms of intravascular lymphoma are not successful in cIVL. This is particularly puzzling since all cIVL tumour cells are by histological definition located within the vessels and not beyond in the brain parenchyma.

###### 

Summary of all patients with intravascular lymphomatosis limited to the CNS (cIVL) reported in the literature

  **Author**                      **Site of involvement**   **Neurological symptoms**                             **Treatment**                                                                                    **Outcome**
  ------------------------------- ------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------
  Baehring et al. \[[@B1]\]       Brain                     Right hemiparesis, dysarthria                         HD-MTX (induction 5, consolidation 10, maintenance 2)                                            CR 20 months after diagnosis
  Baehring et al. \[[@B1]\]       Brain, spinal cord        Proximal spastic paraparesis, psychosis               HD-MTX (induction 12)                                                                            PR 18 months after diagnosis
  Baehring et al. \[[@B1]\]       Brain, nerve roots        Dysarthria, gait disturbance, allodynia               HD-MTX initially (induction 6, consolidation 4), HD-MTX salvage (6 induction, 7 consolidation)   PR until 8 months after diagnosis: PR until 12 months after recurrence
  Baehring et al. \[[@B1]\]       Brain                     Cognitive decline, homonymous hemianopsia, ataxia     HD-MTX (induction 1 cycle)                                                                       Died of disease progression after first cycle of chemotherapy
  Calamia et al. \[[@B15]\]       CNS                       NA                                                    m-BACOD                                                                                          OS 16 months
  Calamia et al. \[[@B15]\]       CNS                       NA                                                    Pro-MACE-CytaBOM                                                                                 OS 44 months
  Bergmann et al. \[[@B6]\]       Brain                     Left-sided hemiparesis                                NA                                                                                               OS 2 months
  Bergmann et al. \[[@B6]\]       Brain                     Spastic paraparesis, left arm paresis                 NA                                                                                               OS 2 months
  DiGiuseppe et al. \[[@B3]\]     Brain                     Mental status changes                                 Pro-MACE-CytaBOM, ifosfamide/VP-16/cisplatin & whole brain irradiation (45 Gy)                   CR 48 months after diagnosis
  Kanda et al. \[[@B16]\]         CNS                       Aphasia, apraxia                                      CHOP, VEMP, radiotherapy                                                                         OS one month
  Aznar et al. \[[@B7]\]          CNS                       Distal paresthesia of the lower limbs, paraparesis    NA                                                                                               OS few months
  Passarin \[[@B8]\]              Brain                     Progressive cognitive deterioration, tetraparesis     NA                                                                                               OS 3--4 weeks
  Natali-Sora et al. \[[@B17]\]   CNS                       Generalized tonic-clonic seizures                     Cyclophosphamide, mitoxantrone, BCNU, methylprednisolone                                         CR 46 months after diagnosis
  Liow et al. \[[@B18]\]          CNS                       NA                                                    CHOP                                                                                             OS 13 months
  Albrecht et al. \[[@B9]\]       Brain                     Cognitive deterioration, aphasia                      NA                                                                                               OS few weeks
  Ferreri et al. \[[@B10]\]       CNS                       NA                                                    CHOP (3 patients), CVP (one patient)                                                             OS less than 4 months
  Holmøy et al. \[[@B12]\]        Brain                     vertigo, diplopia, left-sided hearing loss, aphasia   high-dose corticosteroid pulse therapy                                                           OS 18 weeks
  Momota et al. \[[@B14]\]        Brain                     Left-sided hemiparesis                                HD-MTX, whole brain irradiation                                                                  OS 6 months
  **This case**                   Brain                     Transient amnestic aphasia, gait ataxia               Bonn protocol + rituximab                                                                        CR 29 months after diagnosis

Abbreviations: HD-MTX: high dose methotrexate; CR: complete remssion; PR: partial response; NA: not available; OS: overall survival; m-BACOD: cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate; Pro-MACE-CytaBOM: prednisone, methotrexate (with leucovorin rescue), doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine; VP-16: etoposide; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone; VEMP: vincristine, cyclophosphamide, mercaptopurine, prednisolone; CVP: cyclophosphamide, vincristine and prednisone; Bonn protocol: HD-MTX, ifosfamide, procarbazin, cytarabine, vinca alkaloids, dexamethasone.

Conclusion
==========

Overall, on the base of our case and upon reviewing the literature, we recommend the use of HD-MTX-based polychemotherapy similar to HD-MTX-based protocols for primary (parenchymal) CNS lymphoma in patients with cIVL.
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